Price, Scalability of Lenacapavir as PrEP Curbs Excitement, Expert Says
Although the FDA approval of lenacapavir as a twice-yearly form of preexposure prophylaxis (PrEP) is “momentous,” cost and access curb excitement, according to Jeremiah Johnson, executive director of PrEP4All.
To reap the full benefit of lenacapavir as a form of preexposure prophylaxis (PrEP), it must be accessible, according to Jeremiah Johnson, executive director of PrEP4All.
Generic lenacapavir could cost as low as $35-$46 per person per year, falling to as low as $25 per person per year, depending on demand, a recent study published in The Lancet reads. The list price in the United States is currently $28,218 per person per year.
Jeremiah Johnson
“At the end of the day, the best PrEP for somebody is going to be the one that they can actually access,” Johnson said during a recent interview with Managed Healthcare Executive. “I don't want people to throw the baby out with the bathwater when we have a daily oral generic of Truvada that is less than $1 a day that may be more feasibly scaled, particularly for some of the communities that are going to fall into the cracks of the American healthcare system.”
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Lenacapavir HIV PrEP: Not an AIDS Vaccine, but Vaccine Adjacent
June 19th 2025Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be available to the people who would benefit most from HIV PrEP?
Read More
Trump Budget Axes CDC HIV Prevention, Shifts Care, Experts Warn of Risks
June 10th 2025Although some HIV programs will remain, the proposed cuts in the fiscal year 2026 budget are too severe and will hinder HIV care and research in the United States, according to Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C.
Read More
